猴痘治疗市场－全球产业规模、份额、趋势、机会和预测，按治疗方法（天花疫苗、抗病毒药物、牛痘免疫球蛋白）、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球猴痘治疗药物市场规模为8,700万美元，预计2030年将以9.01%的复合年增长率成长至1.4599亿美元。猴痘治疗药物涵盖多种药物介入措施，包括抗病毒药物和疫苗，主要用于预防和治疗猴痘病毒感染。这些介入措施针对的是一种以类似天花症状为特征的人畜共通传染病。全球猴痘治疗药物市场成长的主要驱动因素是各地猴痘疫情的不断增加。此外，各国政府优先考虑公共卫生防范的倡议，包括策略性储备抗病毒药物和疫苗，也进一步推动了市场成长。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球猴痘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗方法（天花疫苗、抗病毒药物、牛痘免疫球蛋白（VIG））
  • 按最终使用者（医院、专科诊所、门诊手术中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美猴痘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲猴痘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区猴痘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲猴痘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美猴痘治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球猴痘治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Chimerix Inc.
• SIGA Technologies, Inc.
• Emergent BioSolutions Inc.
• Bavarian Nordic A/S
• Hetero Drugs Limited
• Mylan NV
• Piramal Enterprises Limited
• Olon SpA
• Teva Pharmaceutical Industries Limited
• CIDIC Company Limited

第十六章：策略建议

第17章调查会社について・免责事项

The Global Monkeypox Therapeutics Market, valued at USD 87.00 Million in 2024, is projected to experience a CAGR of 9.01% to reach USD 145.99 Million by 2030. Monkeypox therapeutics encompass pharmaceutical interventions, including antiviral drugs and vaccines, primarily utilized for the prevention and treatment of monkeypox virus infections. These interventions address the zoonotic disease characterized by smallpox-like symptoms. The global market for these therapeutics is driven by the increasing incidence of monkeypox outbreaks in various regions. Further impetus stems from governmental initiatives prioritizing public health preparedness, which includes the strategic stockpiling of antiviral treatments and vaccines.

Key Market Drivers

The increasing global incidence of monkeypox outbreaks profoundly influences the therapeutics market by creating an urgent and sustained demand for effective treatments and preventative measures. Each new surge in cases directly translates into a heightened need for antiviral drugs and vaccines to manage symptoms, prevent severe disease, and curb transmission. According to the Pan American Health Organization/WHO, in October 2024, an Epidemiological Update reported 109,699 confirmed cases of mpox globally between January 2022 and September 30, 2024, further indicating a monthly increase of 8% in new cases in September 2024 compared to August, underscoring the ongoing spread of the virus and the persistent threat it poses to public health. This rising incidence drives pharmaceutical companies to allocate resources towards research and development, aiming to innovate and expand their portfolio of monkeypox therapeutics.

Key Market Challenges

The limited availability of specifically approved therapeutic agents for monkeypox presents a substantial challenge to the growth of the Global Monkeypox Therapeutics Market. Current treatment protocols frequently depend on drugs originally developed for smallpox, which may not consistently prove optimal or widely accessible for monkeypox virus infections. This reliance creates a significant barrier to the rapid and widespread deployment of tailored interventions, particularly when considering evolving viral clades and diverse geographical spread.

Key Market Trends

The global monkeypox therapeutics market is experiencing significant evolution, driven by shifts in drug development and preventative strategies. One prominent trend is the **Evolution Towards Oral Antiviral Therapeutic Options**. This movement is crucial for improving patient access, adherence, and facilitating outpatient care, thereby easing the burden on healthcare infrastructure. Oral formulations offer a more convenient alternative to intravenous treatments, which can be critical during outbreaks. For example, NanoViricides, Inc. announced in July 2025 the near-finalization of its adaptive Phase II clinical trial protocol for NV-387, a novel oral antiviral designed to treat monkeypox virus infections, highlighting the ongoing efforts to develop user-friendly treatment options. This aligns with a broader pharmaceutical industry trend where oral drug development remains a priority due to its patient-centric benefits.

Key Market Players

• Chimerix Inc.
• SIGA Technologies, Inc.
• Emergent BioSolutions Inc.
• Bavarian Nordic A/S
• Hetero Drugs Limited
• Mylan N.V.
• Piramal Enterprises Limited
• Olon S.p.A.
• Teva Pharmaceutical Industries Limited
• CIDIC Company Limited

Report Scope:

In this report, the Global Monkeypox Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monkeypox Therapeutics Market, By Treatment:

• Smallpox Vaccine
• Antivirals
• Vaccinia Immune Globulin (VIG)

Monkeypox Therapeutics Market, By End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Monkeypox Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Monkeypox Therapeutics Market.

Available Customizations:

Global Monkeypox Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monkeypox Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
  • 5.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Monkeypox Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Monkeypox Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Monkeypox Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Monkeypox Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Monkeypox Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Monkeypox Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. France Monkeypox Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Monkeypox Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Monkeypox Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Monkeypox Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia Pacific Monkeypox Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Monkeypox Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. India Monkeypox Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Monkeypox Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Monkeypox Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Monkeypox Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. Middle East & Africa Monkeypox Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Monkeypox Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Monkeypox Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Monkeypox Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. South America Monkeypox Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Monkeypox Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Monkeypox Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Monkeypox Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Monkeypox Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Chimerix Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. SIGA Technologies, Inc.
• 15.3. Emergent BioSolutions Inc.
• 15.4. Bavarian Nordic A/S
• 15.5. Hetero Drugs Limited
• 15.6. Mylan N.V.
• 15.7. Piramal Enterprises Limited
• 15.8. Olon S.p.A.
• 15.9. Teva Pharmaceutical Industries Limited
• 15.10. CIDIC Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer